GemVax steps up development of a new drug for an “intractable brain disease” ... announces long-term clinical results in the UK

[Financial News]  GemVax is accelerating global development of a treatment for progressive supranuclear palsy (PSP), a rare neurodegenerative disease. The company shared long-term clinical data on its drug candidate GV1001 at an international academic forum and moved to expand the basis for collaboration on follow-up clinical development.
According to GemVax & KAEL on the 9th, the company presented poster results from an open-label extension of a Phase 2a clinical trial of GV1001 in patients with PSP at Neuro2026, an international research symposium held in London, UK, on the 5th and 6th.
The presentation covered results from a long-term clinical study evaluating the safety and efficacy of GV1001 over 72 weeks. However, specific efficacy measures and statistical significance, among other details, could not be confirmed from the presentation materials.
Neuro2026 is an international academic event co-hosted by CurePSP, a US patient support and research organization, and the UK’s PSPA. Leading researchers in PSP and corticobasal degeneration (CBD) take part to discuss drug development and global clinical-trial trends.
GemVax took part in the event as a gold sponsor, broadening opportunities for collaboration with global researchers and patient organizations. The company plans to incorporate discussions on early diagnosis of PSP, biomarkers and global clinical-trial design into its future development strategy.
The biotech industry views securing long-term safety data and building a global research network as important factors in advancing the development of treatments for rare neurodegenerative diseases. However, the assessment is that actual treatment efficacy and commercialization potential will require further validation through future clinical trials that include control groups.
A GemVax representative said, “We will proceed with follow-up global clinical development, carefully incorporating global clinical-development strategies and biomarker-based disease assessments, among other considerations.”


[email protected] Kim Gyeong-a Reporter